| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 05/03/2001 | WO2001030362A2 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 05/03/2001 | WO2001030359A1 Cholesterol lowering and blood lipids lowering composition |
| 05/03/2001 | WO2001030353A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 05/03/2001 | WO2001030343A1 Pharmaceuticals for treating obesity |
| 05/03/2001 | WO2001030328A2 Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions |
| 05/03/2001 | WO2001030137A1 N-calcium channel knockout animal |
| 05/03/2001 | WO2000074712A3 Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product |
| 05/03/2001 | WO2000072876A3 Prevention and treatment of amyloidogenic disease |
| 05/03/2001 | WO2000065028A3 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR |
| 05/03/2001 | WO2000054813A3 Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| 05/03/2001 | US20010000786 Administering to an obese canine a low supplemental amount of L-carnitine to promote weight loss, increase the lean body mass, enhance satiety and reduce voluntary food intake |
| 05/03/2001 | DE19952147A1 Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung New cyclopropanes, pharmaceutical compositions containing them and methods for their preparation |
| 05/03/2001 | DE19951970A1 Arzneimittel für die Toleranzinduktion Medicines for tolerance induction |
| 05/03/2001 | DE19951702A1 Verwendung von 2-Amino-3,4-dihydro-chinazolinen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten Use of 2-amino-3,4-dihydro-quinazolines for the preparation of a medicament for the treatment or prophylaxis of illnesses caused by ischemic conditions |
| 05/03/2001 | DE19951360A1 Substituierte Indole Substituted indoles |
| 05/03/2001 | CA2389127A1 Human sphingosine kinase gene |
| 05/03/2001 | CA2389020A1 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 05/03/2001 | CA2388974A1 Medicament in order to induce tolerance |
| 05/03/2001 | CA2388965A1 Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions |
| 05/03/2001 | CA2388950A1 Nucleic acids of the human abc1 gene and their therapeutic and diagnostic application |
| 05/03/2001 | CA2388934A1 Micro-cluster liquids and methods of making and using them |
| 05/03/2001 | CA2388924A1 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 05/03/2001 | CA2388637A1 Human fgf-20 gene and gene expression products |
| 05/03/2001 | CA2388599A1 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 05/03/2001 | CA2387652A1 A method of prophylaxis and treatment |
| 05/03/2001 | CA2387506A1 Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
| 05/03/2001 | CA2386750A1 Pharmaceuticals for treating obesity |
| 05/03/2001 | CA2385929A1 Use of gdnf for treating corneal defects |
| 05/02/2001 | EP1096008A2 Human G protein-coupled receptor, PFI-014 |
| 05/02/2001 | EP1095657A2 Compositions for the regulation of cytokine activity |
| 05/02/2001 | EP1095654A2 Use of raloxifene and its analogs for the manufacture of a medicament for the Inhibition of LDL oxidation and atherosclerosis |
| 05/02/2001 | EP1095651A2 Multipor food protection |
| 05/02/2001 | EP1095154A2 Interaction of human beta amyloid precursor protein (beta-app) with human lon-protease like protein (hslon) |
| 05/02/2001 | EP1095036A1 Cinnamic acid derivatives as cell adhesion molecules |
| 05/02/2001 | EP1095021A1 Quinoline derivatives |
| 05/02/2001 | EP1095016A1 Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| 05/02/2001 | EP1095015A2 Sulfonylamino carboxylic acid n-arylamides as guanylate cyclase activators |
| 05/02/2001 | EP1095007A1 Water-soluble zinc pyruvates or their hydrates, method for the production thereof and their use |
| 05/02/2001 | EP1095003A1 Cytokine production and tyrosine kinase inhibitors |
| 05/02/2001 | EP1094828A1 Use of neglected target tissue antigens in modulation of immune responses |
| 05/02/2001 | EP1094824A1 Prophylactic and therapeutic nutritional supplement for creation/maintenance of health-protective intestinal microflora and enhancement of the immune system |
| 05/02/2001 | EP1094816A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 05/02/2001 | EP1094810A1 Use of prenyltransferase inhibitors for preparing a medicine for treating pathologies resulting from heterotrimeric g protein membrane fixation |
| 05/02/2001 | EP1094801A2 Poly(diallylamine)-based bile acid sequestrants |
| 05/02/2001 | EP1094797A1 Transdermal plaster containing at least one active ingredient which influences blood serum lipid levels |
| 05/02/2001 | EP1094712A1 Hypericin and hypericum extract: specific t-type calcium channel blocker, and their use as t-type calcium channel targeted therapeutics |
| 05/02/2001 | EP1094711A1 Methods for eradication of nanobacteria |
| 05/02/2001 | EP0769947B1 Indolinone compounds for the treatment of disease |
| 05/02/2001 | EP0750502B1 Use of phosphorus derivatives of alkaloids for treating endocrinopathies |
| 05/02/2001 | CN1293666A Benzenesulfonamide-derivatives and their use as medicaments |
| 05/02/2001 | CN1293543A Method for producing fat mixture |
| 05/02/2001 | CN1293195A New polycyclicazaindole compound, its preparation method are medicine composition containing same |
| 05/02/2001 | CN1293065A Process for preparing health-care buccal amino acid lozenge |
| 05/02/2001 | CN1065130C Medicine for treatment of diatetes mellitus |
| 05/01/2001 | US6225494 Trisubstituted phenyl derivatives having retinoid agonist or inverse agonist type biological activity |
| 05/01/2001 | US6225486 Composition comprising mixture of free fatty acid conjugated linoleic acid isomers containing at least approximately 92 per cent trans 10, cis 12-octadecadienoic acid |
| 05/01/2001 | US6225448 1gG /transferrin receptor fusion protein |
| 05/01/2001 | US6225355 Process for removing bile salts from a patient and alkylated compositions therefor |
| 05/01/2001 | US6225354 Subjecting unsaponified beeswax to liquid extraction with liquid organic extractant in which primary aliphatic alcohols are soluble; recovering alcohol mixture and isolating alcohols |
| 05/01/2001 | US6225335 3-(4′-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease |
| 05/01/2001 | US6225328 Adamantyl-substituted retinoids and pharmaceutical/cosmetic compositions comprised thereof |
| 05/01/2001 | US6225326 Administering insulin sensitivity enhancer in combination with an .alpha.-glucosidase inhibitor for therapy to reduce side effect for diabetic patient |
| 05/01/2001 | US6225310 Fused 1,2,4-thiadiazine derivatives, their preparation and use |
| 05/01/2001 | US6225308 Tissue selective compounds in the treatment of prostate cancer or benign prostate hypertrophy |
| 05/01/2001 | US6225290 Provides advantages:short term or long term cures and/or treatment, avoids invasive procedures, oral administration, naked dna is used rather than viral vectors, side-effects of long term gene administration can be avoided |
| 05/01/2001 | US6225288 Implicated in modulating apoptosis; treatment of:cardiac and cerebral ischemia/reperfusion injury, spinal cord injury and organ damage during transplantation, chronic neurodegenerative diseases, immunodeficiency, diabetes, alopecia, aging |
| 05/01/2001 | US6225284 Somatostatin peptides |
| 05/01/2001 | US6225117 Antibodies against human IL-12 |
| 05/01/2001 | US6224862 Mixture of prothrombinase and protein; anticoagulant |
| 05/01/2001 | CA2016664C Indole derivative and method of production thereof |
| 05/01/2001 | CA1341222C Preparations of islet amyloid polypeptide (iapp) and antibodies to iapp |
| 04/29/2001 | CA2325069A1 Use of corticotropin releasing factor antagonists and related compositions |
| 04/26/2001 | WO2001029219A1 Human cub-domain-containing protein and gene encoding the same |
| 04/26/2001 | WO2001029206A1 Methods of producing differentiated progenitor cells and lineage-defective embryonic stem cells |
| 04/26/2001 | WO2001029178A2 Epo primary response gene 1, eprg1 |
| 04/26/2001 | WO2001029073A1 Methods for improving secondary metabolite production in fungi |
| 04/26/2001 | WO2001029071A2 Genes associated with obesity and methods for using the same |
| 04/26/2001 | WO2001029070A2 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
| 04/26/2001 | WO2001029049A2 Imidazole derivatives as phosphodiesterase vii inhibitors |
| 04/26/2001 | WO2001029042A1 Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase |
| 04/26/2001 | WO2001029039A1 Synthesis and methods of use of 9-substituted guanine derivatives |
| 04/26/2001 | WO2001029036A2 Allosteric sites on muscarinic receptors |
| 04/26/2001 | WO2001029026A1 Phenyl- and pyridyl-tetrahydro-pyridines having tnf inhibiting activity |
| 04/26/2001 | WO2001029022A1 Benzopyran derivatives |
| 04/26/2001 | WO2001029012A2 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 04/26/2001 | WO2001029011A2 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 04/26/2001 | WO2001029007A1 Pyrazole derivatives as cannabinoid receptor antagonists |
| 04/26/2001 | WO2001028978A1 Bicyclic amino acids as pharmaceutical agents |
| 04/26/2001 | WO2001028567A2 Aminoalkylenephosphonates for treatment of bone disorders |
| 04/26/2001 | WO2001028557A1 Cannabimimetic indole derivatives |
| 04/26/2001 | WO2001028547A1 Food materials useful in preventing and ameliorating metabolic bone diseases and preventives/remedies for metabolic bone diseases comprising these materials |
| 04/26/2001 | WO2001028527A2 Direct compression polymer tablet core |
| 04/26/2001 | WO2001028523A1 Powder pharmaceutical formulations |
| 04/26/2001 | WO2001028497A2 Novel bicyclic cannabinoid agonists for the cannabinoid receptor |
| 04/26/2001 | WO2001028365A1 Dietary supplement |
| 04/26/2001 | WO2001028356A2 Food supplement for increasing lean mass and strength |
| 04/26/2001 | WO2001028353A2 Protein hydrolysates produced with the use of marine proteases |
| 04/26/2001 | WO2001028321A1 Diabetes onset model mammal |
| 04/26/2001 | WO2000056889A3 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/26/2001 | WO2000055139A3 Heterocyclic urea and related compounds useful as anti-inflammatory agents |